Neurocrine Biosciences Overview
Neurocrine Biosciences Target Price
Analysts' 12-month price predictions for NBIX.
Get informed when a big investor buys or sells
+ FollowShare Price
$172.04
Average Target Price
$213.43
24.1% upside
24.1% upside7 analysts in the last 4 months
High: $230 | Low: $195
Analyst Recommendations
No recommendations in the last 4 months.
Revenue & Income Forecast
Analysts' Target Prices
| Date | Analyst | Price Target | Current Upside/Downside | |
|---|---|---|---|---|
| 2026-07-07 | RBC CapitalBrian Abrahams | $195 | 13.3% upside |  |
| 2026-06-30 | UBS | $208 | 20.9% upside | |
| 2026-06-02 | Goldman SachsCorinne Johnson | $213 | 23.8% upside | |
| 2026-05-21 | BernsteinJeffrey Walch | $221 | 28.5% upside | |
| 2026-05-06 | Oppenheimer | $230 | 33.7% upside | |
| 2026-05-06 | Piper Sandler | $207 | 20.3% upside | |
| 2026-04-06 | Oppenheimer | $220 | 27.9% upside | |
| 2026-03-10 | Cantor FitzgeraldJosh Schimmer | $195 | 13.3% upside | |
| 2026-02-23 | Wolfe Research | $160 |  7% downside | |
| 2026-02-17 | Truist FinancialDanielle Brill | $140 | 18.6% downside | |
| 2026-02-12 | Needham | $185 | 7.5% upside | |
| 2026-02-12 | RBC Capital | $177 | 2.9% upside | |
| 2026-02-12 | Wedbush | $151 | 12.2% downside | |
| 2026-02-12 | Morgan Stanley | $173 | 0.6% upside | |
| 2026-02-12 | H.C. Wainwright | $192 | 11.6% upside | |
| 2026-01-23 | UBS | $178 | 3.5% upside | |
| 2026-01-08 | Truist Financial | $169 | 1.8% downside | |
| 2026-01-08 | Morgan Stanley | $175 | 1.7% upside | |
| 2026-01-05 | UBSAshwani Verma | $188 | 9.3% upside | |
| 2025-12-17 | H.C. Wainwright | $198 | 15.1% upside | |
| 2025-12-11 | Stifel Nicolaus | $188 | 9.3% upside | |
| 2025-12-08 | RBC Capital | $180 | 4.6% upside | |
| 2025-10-29 | Truist FinancialDanielle Brill | $172 | 0% upside | |
| 2025-10-29 | UBS | $183 | 6.4% upside | |
| 2025-10-29 | RBC Capital | $160 | 7% downside | |
| 2025-10-29 | Mizuho Securities | $146 | 15.1% downside | |
| 2025-10-29 | Stifel NicolausPaul Matteis | $183 | 6.4% upside | |
| 2025-10-29 | BMO Capital | $147 | 14.6% downside | |
| 2025-10-29 | NeedhamAmi Fadia | $184 | 7% upside | |
| 2025-10-29 | Piper Sandler | $179 | 4% upside | |
| 2025-10-29 | JefferiesAkash Tewari | $174 | 1.1% upside | |
| 2025-10-20 | Morgan Stanley | $168 | 2.3% downside | |
| 2025-10-09 | UBSAshwani Verma | $195 | 13.3% upside | |
| 2025-07-31 | Guggenheim | $175 | 1.7% upside | |
| 2025-04-28 | Canaccord Genuity | $158 | 8.2% downside | |
| 2025-04-22 | H.C. WainwrightAndrew Fein | $168 | 2.3% downside | |
| 2025-03-07 | Morgan Stanley | $150 | 12.8% downside | |
| 2025-01-08 | UBSAshwani Verma | $162 | 5.8% downside | |
| 2024-10-31 | BMO CapitalEvan David Seigerman | $121 | 29.7% downside | |
| 2024-10-22 | OppenheimerJay Olson | $192 | 11.6% upside | |
| 2024-10-10 | Raymond JamesDanielle Brill | $155 | 9.9% downside | |
| 2024-09-13 | BMO CapitalEvan David Seigerman | $128 | 25.6% downside | |
| 2024-09-09 | BarclaysCarter Gould | $160 | 7% downside | |
| 2024-08-29 | RBC CapitalBrian Abrahams | $136 | 20.9% downside | |
| 2024-08-29 | Piper SandlerDavid Amsellem | $159 | 7.6% downside | |
| 2024-07-12 | Morgan StanleyJeffrey Hung | $170 | 1.2% downside | |
| 2024-06-06 | RBC CapitalBrian Abrahams | $141 | 18% downside | |
| 2024-05-28 | UBSAshwani Verma | $193 | 12.2% upside | |
| 2024-05-13 | Evercore ISICory Kasimov | $175 | 1.7% upside | |
| 2024-05-02 | Canaccord GenuitySumant Kulkarni | $164 | 4.7% downside | |